SCHEDULE 13D/A: RA Capital Increases Stake in VOR Biopharma to 31.8% Through $50 Million Pre-Funded Warrant Investment

RA Capital Management and its affiliates have significantly increased their beneficial ownership in VOR Biopharma Inc. to 31.8% through a $50 million private placement of pre-funded warrants, contingent on stockholder approval for share issuance and charter amendment.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the "Reporting Persons") collectively beneficially own 39,739,850 shares of VOR Biopharma Inc. common stock, representing 31.8% of the outstanding class.
• RA Capital Healthcare Fund, L.P. ("the Fund") directly holds 37,820,713 shares, representing 30.3% of the class.
• On June 25, 2025, VOR Biopharma entered into a securities purchase agreement for a private placement of Pre-Funded Warrants to purchase up to 700,000,000 shares of common stock at $0.25 per share.
• The Fund purchased Pre-Funded Warrants exercisable for up to 200,000,000 shares in this private placement for $50,000,000, funded by its working capital.
• These new Pre-Funded Warrants have an exercise price of $0.0001 per share and become exercisable upon stockholder approval of the share issuance and a charter amendment to increase authorized shares.
• Existing Pre-Funded Warrants held by the Fund for up to 200,000,000 shares are not currently exercisable due to the limitation on authorized but unissued shares.
• Certain stockholders, including the Fund, representing approximately 63% of VOR Biopharma's total voting power as of June 26, 2025, have entered into Voting and Support Agreements to vote in favor of the necessary stockholder approvals.
• The Issuer has agreed to file a registration statement for the resale of the Pre-Funded Warrant shares within 30 days after stockholder approval and use commercially reasonable efforts to make it effective within 75 days.

Sentiment

Score: 7

Explanation: The document indicates a significant capital infusion from a major investor, RA Capital, which is a strong positive. The high percentage of voting support for the necessary approvals (63%) suggests a high likelihood of the transaction proceeding. However, the contingency on stockholder approval and the existing limitation on authorized shares introduce some uncertainty and potential for delay, preventing a higher score.

Positives

• Significant capital infusion of $50,000,000 into VOR Biopharma from a major institutional investor, RA Capital.
• The investment is structured via pre-funded warrants at a low exercise price ($0.0001), indicating a strong commitment and belief in future value.
• Voting and Support Agreements from stockholders representing approximately 63% of voting power significantly increase the likelihood of obtaining the necessary stockholder approvals for the warrant exercise and charter amendment.
• The Issuer has committed to registering the shares for resale, providing a clear path to liquidity for the investors.

Negatives

• The exercise of the new Pre-Funded Warrants, and thus the full capital infusion, is contingent on stockholder approval and a charter amendment to increase authorized shares, introducing a dependency.
• Existing Pre-Funded Warrants are currently not exercisable due to insufficient authorized shares, highlighting a past limitation that the new charter amendment aims to address.
• The beneficial ownership blocker (9.99%, adjustable to 19.99%) limits immediate full exercise of warrants, potentially delaying full capital deployment or influence.

Risks

• Risk of not obtaining stockholder approval for the issuance of Pre-Funded Warrant Shares and the necessary charter amendment to increase authorized shares, which would prevent the exercise of the new warrants and the full realization of the capital raise.
• Potential for dilution for existing shareholders once the Pre-Funded Warrants are exercised, as they represent up to 700,000,000 new shares (200,000,000 for RA Capital Fund).
• The 9.99% beneficial ownership blocker (adjustable to 19.99%) on warrant exercise could limit the investor's ability to fully convert their warrants and exert influence if not adjusted.

Future Outlook

The company anticipates securing stockholder approval for the issuance of shares underlying the Pre-Funded Warrants and a charter amendment to increase authorized shares, which will enable the exercise of the newly issued warrants and facilitate a significant capital infusion. Following approval, the Issuer is committed to filing a registration statement for the resale of these shares within 30 days and aiming for effectiveness within 75 days.

Industry Context

This significant investment by RA Capital, a prominent healthcare-focused investment firm, underscores continued investor confidence in the biopharmaceutical sector, particularly in companies like VOR Biopharma. Such private placements are a common financing mechanism for biotech firms to raise capital for R&D and operational needs, especially when public market conditions are challenging or when seeking strategic long-term partners. The structure involving pre-funded warrants and contingent stockholder approval is typical for substantial equity raises that could lead to significant dilution, requiring careful management of corporate governance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution upon the exercise of the Pre-Funded Warrants (up to 700,000,000 new shares). However, the capital raise provides funding for the company's operations and strategic initiatives, which could benefit long-term shareholder value.
• Company (VOR Biopharma): Receives a substantial capital infusion of $50,000,000, strengthening its financial position and supporting its operations and development programs.
• RA Capital Management: Increases its strategic stake and influence in VOR Biopharma, aligning its interests with the company's long-term success.

Next Steps

• Obtain stockholder approval for the issuance of Pre-Funded Warrant Shares and an amendment to the Issuer's charter to increase authorized shares.
• Issuer to file a registration statement covering the resale of the June 2025 Registrable Securities within 30 days after Stockholder Approval.
• Issuer to use commercially reasonable efforts to cause the registration statement to become effective as soon as practicable, but no later than 75 days after initial filing.
• Issuer to keep the registration statement effective until the Pre-Funded Warrant Shares can be sold or resold without restriction.

Key Dates

Recommendation

Keywords

VOR Biopharma, RA Capital Management, Schedule 13D, SEC filing, Private Placement, PIPE, Pre-Funded Warrants, Stockholder Approval, Capital Raise, Biopharma Investment, Equity Financing, Beneficial Ownership, Corporate Governance, Share Dilution